MedTrace Logo

Pharmacology of Cognition in Schizotypal Personality Disorder

NCT00353379 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2017-02-10

No results posted yet for this study

Summary

This study will determine the effectiveness of guanfacine in improving cognitive and functional impairments in schizotypal personality disorder.

Conditions

  • Schizotypal Personality Disorder
  • Personality Disorders

Interventions

DRUG

Guanfacine

Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.

DRUG

Placebo

Participants will take placebo for 6 weeks.

Sponsors & Collaborators

Principal Investigators

  • Larry J. Siever, MD · Bronx VA Medical Center/Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1995-09-30
Primary Completion
1997-05-31
Completion
1997-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353379 on ClinicalTrials.gov